Search Results

Numerous GLP-1 RA and SGLT2i presentations touted their clinical results, providing continued excitement for our BETonMACE program, which observed a non-prespecified 63% reduction in MACE and heart failure hazard among patients taking next-generation glucose lowering drugs

TCB strengthens its capital markets and operational advisory businesses with the addition of numerous notable Strategic Advisory Board members from across the healthcare and life sciences sectors

Glaukos Corporation announced today that it will present multiple scientific abstracts at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 5-8, 2024 in Boston, MA.

PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is thrilled to announce that allowance has been granted for the Composition of Matter of its PharmAla-1 (P-1) molecule by the US Patent and Trademark Office (USPTO).

Glaukos Corporation (NYSE: GKOS) announced today that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held November 3-6, 2023 in San Francisco, CA.

Gemelli Biotech and its technologies will be featured in numerous presentations at DDW 2024.

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”) announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, will participate in a panel titled, “Understanding Inflammation and the Implications on Diseases,” at the BioFlorida Conference on Thursday October 12th from 10:30-11:30 AM EDT.

Nova Eye Medical Limited is pleased to announce that its proprietary iTrack™ technology portfolio for canaloplasty, a stent-free minimally invasive glaucoma procedure, will be featured in 18 scientific presentations and posters during the official program of the 2023 American Society of Cataract and Refractive Surgery (ASCRS), taking place May 5-8, 2023, in San Diego, California.

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that, after careful deliberation, its Board of Directors (the “Board”) unanimously concluded that the notice (the “Notice”) submitted by Ted D. Kellner purporting to nominate himself, Robert L. Chioini and Todd Deutsch for election to the Company’s Board at the 2023 Annual Meeting of Stockholders (the “2023 Annual Meeting”) fails to comply with the Company’s Bylaws (the “Bylaws”) and is invalid.